Second chance: new combo tackles hepatitis c in HIV patients

NCT ID NCT00221650

Completed Disease control Sponsor: University Hospital, Bordeaux Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tested a combination of peginterferon alfa2a and ribavirin in 17 HIV-positive people with chronic hepatitis C who had not responded to earlier treatment. Participants received weekly injections and daily pills for 48 weeks. The main goal was to see if the virus became undetectable 24 weeks after treatment ended.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: peginterferon alfa2a and ribavirin
What this could lead to: If successful, this could offer a second-line treatment option for hepatitis C in people with HIV who did not respond to initial therapy.
What could go wrong: This is a very small, early-phase study (17 participants) with no control group. Results may not apply broadly, and the combination can cause flu-like symptoms, anemia, and depression.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEPATITIS C, CHRONIC are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

chronic hepatitis C virus infection hepatitis C virus infection HIV infectious disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HEPATITIS C, CHRONIC HIV INFECTIONS TREATMENT FAILURE

Contacts and locations

Locations

Hôpital Pellegrin, Federation des Maladies Infectieuses, Pr RAGNAUD

Bordeaux, 33076, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.